Plain-English translation of NCT06650163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called Zr-89 crefmirlimab berdoxam immunoPET that helps doctors see where immune cells are active in brain tumors. The scan uses a special radioactive tracer (a harmless marker) that attaches to immune cells, allowing doctors to get a clearer picture of your tumor before surgery. This could help doctors understand your tumor better and plan the best treatment approach.
Current imaging scans don't always show doctors exactly where immune cells are gathering in brain tumors. This new scan aims to fill that gap by providing clearer pictures of immune activity, which could help doctors predict how well treatment will work and improve surgical planning.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the new imaging medication intravenously (into your vein) about 3 days before your scheduled brain tumor surgery. About 24 hours after the injection, you would undergo the special imaging scan and advanced MRI scans. You would then proceed with your standard surgical tumor removal and biopsy as planned. After surgery, you would have follow-up care as part of your regular treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States